The clock is ticking down. On or around August, 2018 Prime Minister Trudeau will sign the Cannabis Act - fully legalizing recreational marijuana in Canada.
With mere months until this $22.6 billion market, which includes retail cannabis and all related products and services, is ripped wide open, there’s a major problem most investors are ignoring: there’s not enough pot to go around.
Licensed cannabis growers only have about 60,000 kg per year of capacity. That’s well short of the 900,000 kg Canadians are expected to consume in the first 12 months after legalization.
What could that mean? In one word - price shocks.
After introducing the world’s first “cannabis streaming” model in 2017, they now have exposure to effectively 2,000,000 square feet of marijuana cultivation space.
They’re poised to participate in every link of the cannabis value chain - from production and distribution to medical applications, nutraceuticals and beverages.
#1 The Great Canadian Marijuana Explosion
In November 2017, the proposed Cannabis Act was passed by the lower house of the Canadian Parliament and is now with the Senate. It is expected that the law will be fully enacted by the end of summer, 2018, opening up all of Canada to legalized cannabis.
That watershed moment is only a few months away.
The economic impact is predicted to be truly massive. For companies like Cannabis Wheaton, it’s possibly a once in a lifetime opportunity.
Consider that the number of medical marijuana patients has already tripled in the last year from around 100,000 to 300,000 and continues to grow at seven percent month over month.
Right now, licensed producers in Canada only provide about seven percent of the potential recreational demand, serving a medical marijuana patient base of 300,000 people.
With full legalization in place, Deloitte estimates the total economic impact of the industry could be $22.6 billion annually - more than the combined sales of beer, wine and spirits.
Canadians will be able to order pot to their door, allowing for easy consumption on a scale never before imagined. That means demand is expected to spike, big time.
Right now, cannabis producers are in a tight spot. Canada currently has just over 100 licensed producers authorized to produce cannabis and only 40 producers authorized to sell cannabis. They grow about 60,000 kg of pot, a mere 7 percent of the potential demand once pot is legalized this summer.
The most recent data by Marijuana Policy Group asserts that demand for recreational cannabis in Canada will be much stronger than expected.
It could exceed 900,000 kgs next year.
Even if every funded square foot of growing space comes online as expected, with no delays whatsoever - we could still be facing a supply shortage through 2021.
Production, distribution, marketing: it’s all in need of rapid expansion.
And, that only accounts for Canadian demand. With legalization sweeping across the globe, including huge markets like California: we may literally run out of pot.
Cannabis Wheaton, thanks to its streaming model, access to capital and market expertise, is well positioned to exploit the need for future expansion.
(Click to enlarge)
And, with legalization going global - Cannabis Wheaton could become a future cannabis “multi-national,” serving consumers around the world.
#2 A Unique Streaming Business Model
It’s the first company to propose “cannabis streaming” - bank-rolling the growth plans of licensed producers in exchange for equity and a steady stream of royalties or taking possession of a portion of the actual pot.
The streaming business model is incredibly attractive. It gives you all the upside exposure of individual LPs, with incredible diversification - and fewer operational headaches.
That’s why royalty companies like Franco Nevada in the mining industry ($13.31b market cap) are typically much larger than the companies they partner with and command significantly higher valuation multiples.
CBW has signed partnership agreements with 17 facilities across six provinces, with a combined 2.0 million effective square feet of cannabis growing space.
The company also has partnerships with 39 clinics, with access to over 30,000 registered medical marijuana patients. They’re actively growing that network.
And, here’s the best part - Cannabis Wheaton’s royalty-based business model is designed to allow it to earn immediately from profitable relationships.
They also have tremendous diversification. With interests in numerous operations, if one crop fails - CBW can turn to another producer without breaking a sweat.
Cannabis Wheaton is building a pan-Canadian network of streaming partners - including producers and distributors - just as it prepares for a potential revolutionary expansion in demand.
Check out its streaming partners below:
And, with legalization on the horizon, a whole new class of startup companies are eager to take advantage of this potential $22.6 billion market.
Cannabis Wheaton recently launched its “Wheaton Licensing Program,” to assist applicants wishing to become Licensed Producers with knowledge of the market.
Think of it as an “incubator” for potential cannabis producers and distributors, all of which could be future streaming partners or acquisition targets.
As the industry grows, Cannabis Wheaton aims to be at the center of it all.
#3 “Downstream” Leverage
Eventually - however - supply will catch up with demand. Marijuana scarcity premiums will shrink. In response, the company is aggressively climbing the value chain.
Over the last year, they’ve become a lot more vertically integrated. They plan to participate economically in every part of the marijuana value chain.
The structure they use to talk about this system is the oil and gas terminology of upstream, midstream and downstream.
Upstream is all the cultivation – where they collect royalties from their streaming partners or can take physical possession of the cannabis to sell into a higher value channel where higher margins can be captured.
Midstream is where the product goes after it leaves the grow facilities. Just as it’s playing out in the U.S., lot of cannabis will be consumed in dry forms or oils.
Edibles, beverages and other innovative formats are increasingly popular and today account for at least 50% of products consumed in recreational US states like Colorado and California.
Cannabis Wheaton has responded by going on a dealmaking spree. They bought Dosecann, which has extraction and R&D facilities for developing higher margin offerings.
Downstream is all the straight to consumer distribution channels. Cannabis Wheaton has split these efforts into three channels: medical, domestic retail, and international.
In February 2018, they secured a distribution deal and ownership stake in Inner Spirit - a market leader in the franchising of retail cannabis dispensaries in Canada.
They’ve also partnered with Province Brands - which aims to become the first company to develop a premium line of beverages brewed exclusively from cannabis.
Along with its partnerships, Cannabis Wheaton has entered into a distribution alliance with a national independent convenience store chain. The agreement will give Wheaton a 10-year exclusive relationship with the nation-wide store chain for medical cannabis distribution.
In a recent interview, CEO Chuck Rifici said these deals could “take us from a wholesale per gram cost for a dry flower of 4 or 5 bucks, into a wholesale refined good - which could be 5 or 6 times the revenue per gram equivalent.” That’s a massive competitive advantage.
Cannabis Wheaton also have their eyes set on emerging legal markets in Europe and Latin America. In January, they announced the acquisition of 80 percent of Uruguay cannabis company Inverell - which produces high grade CBD oil at incredible margins.
The international market for cannabis is projected to hit $31.4 billion by 2021.
#4 Broad Access to Capital
In November 2017, Cannabis Wheaton (TSX-V:CBW; OTC: CBWTF) completed a private placement of convertible debenture units for $35 Million in additional capital. Following that in January 2018, the company raised an additional $100 million through another offering of convertible debentures.
That’s on top of $50 million raised in June 2017. This gives The Company a full war chest to finance deals, acquisitions and new streaming agreements.
Cannabis Wheaton recently announced a $10 million debt financing deal with Beleave Inc., the parent company of a licensed producer, built around a novel debt instrument dubbed the Debt Obligation repayable in Product Equivalent, or “DOPE Note”.
The DOPE Note model allows the company to loan Beleave up to $10 million and receive repayment in cannabis, which can be sold by Beleave to its patients and/or customers or the company can sell on to other distributors.
The first $5 million has already been advanced.
Expect to see more of these deals as Cannabis Wheaton continues to aggressively pursue every sector of the marijuana market, in Canada and abroad.
#5 Highly Connected & Experienced Management Team
CEO Chuck Rifici is a well-known figure in the cannabis industry, the co-founder of Canada’s largest government-sanctioned marijuana producer, Canopy Growth Corp., and the man who took it public in April 2014. Canopy has a $6.0 billion market cap and is the largest public cannabis company in the world.
A pioneer of the legal pot trade, Rifici has also sat on the board of a number of industry standouts, including Supreme Pharmaceuticals Inc. (FIRE), CannaRoyalty Corp. (CRZ) and Aurora Cannabis Inc. (ACB).
Rifici has the political connections to make it in the world of pot, still an industry in need of strong government direction. He is the former chief financial officer of the Liberal party, and the company’s strategic advisor Rick Dykstra is a former Conservative Member of Parliament and former Ontario party president.
Cannabis Wheaton is well positioned to navigate the regulatory environment. Rifici and Dykstra can count on legal knowledge from industry expert Hugo Alves, a former partner at Bennett Jones LLP, founder of the firm’s Cannabis Group and another industry pioneer and now President and Director of Cannabis Wheaton.
Alves has advised over 15 of the leading licensed producers, as well as 60 ancillary cannabis businesses. Possibly no one in Canada knows more about the regulatory environment than him, and possibly no one could give better advice as to how to navigate the changing waters of the legal cannabis industry than him.
With this management team in place and its unique business model to back it up, Cannabis Wheaton considers itself better positioned than any other firm to take full advantage of the coming cannabis boom.
As we speak, the global legalization wave is picking up steam.
The state of California, one of the largest cannabis markets in the world, started selling recreational pot early this year. By some estimates, the legal cannabis market in NorthAmerica could be $24.5 billion by 2021.
While federal law in the United States may take some time to change, you can be sure that Germany, Ireland, France, the United Kingdom, Brazil, and a host of other countries will take notice and may also join the cannabis craze.
If investors want to get in on the action, they should consider now as a very good time.
More companies in the therapeutics industry:
Cara Therapeutics Inc (NASDAQ:CARA) has had a particularly strong year in 2017. At the beginning of August, the company had seen over 175 percent growth, although it has since corrected slightly. The company focuses primarily in the pain therapeutics market, which is an estimated $83-billion per year industry.
The company approaches the pain therapeutics market in a new way. Focusing on drugs which target kappa opioid receptors, Cara’s game-changing medication comes without the side effects of actual opiates. While the drug is still an opioid, it targets the body’s peripheral nervous system, leaving users without the life-ruining side effects that other medications may cause.
The company’s ground-breaking pain management medication, in addition to the substantial market of patients who need care, provide an excellent platform for growth within the industry. Investors should watch closely as this company makes its way into this highly competitive market.
Insys Therapeutics (NASDAQ:INSY) is generally known as a “marijuana stock” but it would be a bit of a misnomer to lump this company in with pot stocks. Insys’ main product is a sublingual pain medication known as Subsys. However, using the same proprietary sublingual spray technology and their advanced knowledge of synthetic cannabinoids, the company is at the forefront of a new pharmaceutical movement.
Founded in 1990, Insys has been around the block. The company clearly has staying power and investors have taken note. With a market cap of nearly $700M, Insys is a promising investment for those interested in dipping their toes into the marijuana realm.
Compass Diversified Holdings (NYSE:CODI) is a holdings company which rings true to its name. Its portfolio is diversified and expansive. The company has been incredibly successful over the past 20 years, in its acquisitions and the management of its acquisitions.
Compass Diversified is included in this list due to its Manitoba Harvest holding. Manitoba Harvest is a leading hemp foods producer and distributor, priding itself on high quality and easily accessible products.
Innovative Industrial Properties (NYSE:IIRP) is set to boom in the coming years. The company has formulated a strategy to target properties for acquisition and management to be leased to state-licensed marijuana growers, a market which is certain to flourish. Innovative Industrial’s leasing plan is simple: the tenant is responsible for everything from taxes to maintenance. The company’s hands-off approach allows for a steady stream of revenue with little oversight.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) is a company that is diving deep into cannabinoid therapies. Currently, the company has only two drugs in development; ZYN001 and ZYN002. ZYN001, a THC pro-drug patch, aims to treat a number of conditions through a revolutionary transdermal delivery system while ZYN002, another transdermal delivery system, this time through a gel, is the first and only synthetic non-psychoactive CBD drug of its kind. And Zynerba has the patents on both products.
Zynerba Pharmaceuticals is another company which has seen modest growth as the marijuana push gains speed. The company, which is at the forefront of new treatments focusing on THC, is set to make out like a bandit upon legalization. Not only will the act open more doors for the company, it will also bring well-deserved notoriety.
By. Charles Kennedy
**IMPORTANT! BY READING OUR CONTENT YOU EXPLICITLY AGREE TO THE FOLLOWING. PLEASE READ CAREFULLY**
FORWARD-LOOKING STATEMENT. Statements in this communication which are not purely historical are forward-looking statements and include statements regarding beliefs, plans, intent, predictions or other statements of future tense. Forward looking statements in this article include: that the Canadian government will fully legalize and regulate cannabis this year; that the Canadian medical and recreational markets combined will be worth $8 billion in gross sales in the year after legalization; that Cannabis Wheaton Income Corp. (“Cannabis Wheaton”) can raise funds and partner quickly with new firms looking to get into the Cannabis industry and access the expertise of Cannabis Wheaton’s management team and non-dilutive capital; that there will likely be a supply shortage; that, if cannabis markets open up in other industrialized countries, the global cannabis market could expand exponentially; that Cannabis Wheaton may be able to help supply cannabis to markets outside Canada; that producers will need to obtain additional financing from companies like Cannabis Wheaton; that Canadian users of cannabis will consume 900,000 kg next year; that Cannabis Wheaton could become a future cannabis “multi-national”; that Cannabis Wheaton can reach EBITDA margins of 50%; and that the cannabis market in Canada could reach $30 billion by 2024 and in North America reach $24.5 billion by 2021. Forward-looking information is based on the opinions and estimates of Cannabis Wheaton at the date the information is made, and is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking information. Forward looking statements involve known and unknown risks and uncertainties which may not prove to be accurate. Actual results and outcomes may differ materially from what is expressed or forecasted in these forward-looking statements. Matters that may affect the outcome of these forward looking statements include: that Cannabis may not be legalized on the timeline as expected or at all; that markets may not materialize as expected; that cannabis may not turn out to have as large a market as thought or be as lucrative as thought as a result of competition or other factors; that Cannabis Wheaton may not be as able to diversify or scale up as thought because of potential lack of capital, lack of facilities, regulatory compliance requirements in Canada or outside of Canada or lack of suitable employees, partners or suppliers; that Cannabis Wheaton may not be able to raise funds and offer better conditions to potential partners than competitors in the cannabis industry; that partners of Cannabis Wheaton may not be granted licenses or additional capacity under existing or newly applied for licenses for them to grow for the cannabis market; that foreign governments may not allow Cannabis Wheaton to operate in their countries; that actual operating performance of the facilities affiliated with Cannabis Wheaton do not meet expectations; that competition quickly develops; that Cannabis Wheaton may not be able to retain key employees, partners and suppliers; costs may be higher than expected and profits therefore lower; competitors may capture most or all of the increased market demand; and other risks affecting the Company in particular and the cannabis industry generally, including without limitation risks related to most agricultural crops, including crop failure. The forward-looking statements in this document are made as of the date hereof and the Company disclaims any intent or obligation to update such forward-looking statements except as required by applicable securities laws.
PAID ADVERTISEMENT. This communication is a paid advertisement and is not a recommendation to buy or sell securities. Oilprice.com, Advanced Media Solutions Ltd, and their owners, managers, employees, and assigns (collectively, “we” or the “Company”) has been paid by the profiled company or a third party to disseminate this communication. In this case the Company has been paid by Cannabis Wheaton seventy-five thousand US dollars for this article and certain banner ads. This compensation is a major conflict with our ability to be unbiased, more specifically:
This communication is for entertainment purposes only. Never invest purely based on our communication. Gains mentioned in our newsletter and on our website may be based on end-of- day or intraday data. If we own any shares we will list the information relevant to the stock and number of shares here. We have been compensated by Cannabis Wheaton to conduct investor awareness advertising and marketing for [TSX-V:CBW and OTC: CBWTF]. Oilprice.com receives financial compensation to promote public companies. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the company. The third party, profiled company, or their affiliates may liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our alerts experience a large increase in volume and share price during the course of investor awareness marketing, which often end as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price is likely to occur.
We do not guarantee the timeliness, accuracy, or completeness of the information on our site or in our newsletters. The information in our communications has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct.
SHARE OWNERSHIP. The owner of Oilprice.com owns shares of this featured company and therefore has an additional incentive to see the featured company’s stock perform well. The owner of Oilprice.com will not notify the market when it decides to buy more or sell shares of this issuer in the market. The owner of Oilprice.com will be buying and selling shares of the featured company for its own profit. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities.
NOT AN INVESTMENT ADVISOR. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. ALWAYS DO YOUR OWN RESEARCH and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment.
INDEMNIFICATION/RELEASE OF LIABILITY. By reading this communication, you agree to the terms of this disclaimer, including, but not limited to: releasing the Company, its affiliates, assigns and successors from any and all liability, damages, and injury from the information contained in this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LEGAL ADVISORY. Investing in companies associated with the cannabis industry may be illegal in the jurisdiction where a reader resides. Before investing in any public company involved in the cannabis industry, potential investors should check with their legal advisor as to whether an investment will breach local or federal law.
RISK OF INVESTING. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell securities.